



February 05, 2025

To,
Listing/ Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIP CODE: 543748

Dear Sir/Madam,

To,
Listing/ Compliance Department
**National Stock Exchange of
India Limited**
"Exchange Plaza", Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
SYMBOL: AARTIPHARM

**Sub: Integrated Filing (Financial) for the
Quarter ended December 31, 2024**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we hereby inform the Exchanges about the Integrated Filing (Financial) for the Quarter ended December 31, 2024.

Please take the same on your records.

Thanking you,

Yours faithfully,
For **AARTI PHARMALABS LIMITED**

JEEVAN MONDKAR
COMPANY SECRETARY AND LEGAL HEAD
ICSI M. NO. A22565

Encl. a/a.

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655



A) Financial Results

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T: +91 22 67976666 | F: +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T: +91 260 2400467, +91 99099 94655

AARTI PHARMALABS LIMITED							
STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024							
Sr. No.	Particulars	₹ lakhs except EPS)					
		Quarter Ended			Nine Months Ended		Annual
		31st Dec 2024 (Audited)	30th Sept 2024 (Audited)	31st Dec 2023 (Audited)	31st Dec 2024 (Audited)	31st Dec 2023 (Audited)	31st March 2024 (Audited)
	Income						
	a) Revenue from Operations	47,094.72	37,729.43	37,303.06	124,172.81	108,731.46	150,213.20
	b) Other Income	1,193.57	294.66	46.39	1,699.52	532.15	1,100.91
1	Total Income	48,288.30	38,024.09	37,349.45	125,872.33	109,263.62	151,314.11
	EXPENSES						
	a) Cost of Materials Consumed	24,290.76	19,637.69	19,111.01	63,026.51	58,187.83	76,157.11
	b) Purchases of Stock-in-Trade	243.52	2,000.32	-	2,409.29	1,375.98	1,375.98
	c) Changes in Inventories of Finished Goods, Work-in-progress and Stock-in-Trade	(914.95)	(3,655.86)	(532.44)	(3,518.79)	(3,071.90)	(2,336.12)
	d) Employee Benefits Expense	3,901.78	3,547.42	3,429.43	11,150.17	9,565.97	13,033.33
	e) Finance Costs	970.28	539.33	435.83	1,934.48	1,221.08	1,663.46
	f) Depreciation and Amortisation Expenses	2,104.32	1,889.28	1,693.63	5,822.86	4,868.95	6,601.38
	g) Other Expenses	8,074.58	7,722.61	6,467.55	22,763.89	18,792.13	27,367.04
2	Total Expenses	38,670.29	31,680.79	30,605.01	103,588.42	90,940.05	123,862.19
3	Profit before Exceptional Items and Tax (1-2)	9,618.00	6,343.31	6,744.44	22,283.90	18,323.57	27,451.93
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	9,618.00	6,343.31	6,744.44	22,283.90	18,323.57	27,451.93
	Tax expense						
	a) Current Year Tax	1,750.87	1,279.47	1,300.00	4,187.02	3,436.00	4,912.00
	b) Short/(Excess) Provision of earlier year	-	-	-	-	-	(306.27)
	c) Deferred Tax	514.78	280.27	625.00	1,246.53	1,125.00	2,781.65
6	Total Tax Expenses	2,265.65	1,559.74	1,925.00	5,433.55	4,561.00	7,387.39
7	Profit for the period (5-6)	7,352.35	4,783.57	4,819.44	16,850.35	13,762.57	20,064.54
	Other Comprehensive Income (OCI)						
	a. Items that will be reclassified to Statement of Profit and Loss	(187.42)	(117.30)	70.39	(327.87)	124.68	13.31
	b. Items that will Not be reclassified to Statement of Profit and Loss						
8	Total Other Comprehensive Income	(187.42)	(117.30)	70.39	(327.87)	124.68	13.31
9	Total Comprehensive Income for the period (7+8)	7,164.94	4,666.27	4,889.82	16,522.48	13,887.25	20,077.85
10	Earnings per Equity share:						
	Basic Earnings Per Share (EPS) (₹)	8.11	5.28	5.32	18.59	15.19	22.14
	Diluted Earnings Per Share (EPS) (₹)	8.11	5.27	5.32	18.58	15.19	22.14
11	Paid-up Equity Share Capital (Face Value of Rs. 5/-each)	4,531.30	4,531.30	4,531.30	4,531.30	4,531.30	4,531.30
12	Reserves excluding Revaluation Reserves as at Balance Sheet date						157,614.58

- The Financial Results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- The above Results for the Quarter and Nine Months ended December 31, 2024, have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on February 5, 2025
- The Company has only one reportable segment i.e. Pharmaceuticals.
- The Board of Directors at its meeting held on 5th February 2025, has declared an interim dividend of Rs. 2.50/- (50%) per equity shares of Rs.5/-each.
- The aforesaid financial results will be uploaded on the Company's website at www.aartipharmalabs.com and are also available on the website of BSE limited www.bseindia.com & the National Stock Exchange of India Limited www.nseindia.com.
- Figures for the previous period have been regrouped or rearranged wherever necessary.

For Aarti Pharmalabs Limited


 Place : Mumbai
 Date: 5th February 2025



 Hetal Gogri Gala
 Vice Chairperson & Managing Director

AARTI PHARMALABS LIMITED
www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

 Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
 Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

AARTI PHARMALABS LIMITED							
STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024							
Sr. No.	Particulars	(₹ lakhs except EPS)					
		Quarter Ended			Nine Months Ended		Year Ended
		31st Dec 2024 (Audited)	30th Sept 2024 (Audited)	31st Dec 2023 (Audited)	31st Dec 2024 (Audited)	31st Dec 2023 (Audited)	31st March 2024 (Audited)
	Income						
	a) Revenue from Operations	53,777.82	45,802.58	44,869.12	155,129.75	134,683.81	185,260.62
	b) Other Income	502.77	448.28	139.05	1,172.67	286.05	489.50
1	Total Income	54,280.59	46,250.87	45,008.17	156,302.42	134,969.86	185,750.12
	Expenses						
	a) Cost of Materials Consumed	26,118.91	22,057.64	21,496.32	70,157.20	65,691.34	85,844.71
	b) Purchases of Stock-in-Trade	786.57	9,810.20	3,846.22	19,290.63	12,231.55	18,221.79
	c) Changes in Inventories of Finished Goods, Work-in-progress and Stock-in-Trade	625.30	(8,310.18)	(899.49)	(4,535.26)	(1,163.50)	(1,994.77)
	d) Employee Benefits Expense	4,163.07	3,772.97	3,615.54	11,859.41	10,100.41	13,840.74
	e) Finance Costs	997.44	550.56	447.75	2,031.31	1,253.95	1,721.47
	f) Depreciation and Amortisation Expenses	2,303.75	2,088.32	1,877.30	6,408.82	5,411.35	7,323.53
	g) Other Expenses	9,223.00	9,104.59	7,242.70	26,483.34	20,970.84	30,743.77
2	Total Expenses	44,218.03	39,074.11	37,626.34	131,695.44	114,495.94	155,701.24
3	Profit before tax before Exceptional Items (1-2)	10,062.56	7,176.76	7,381.83	24,606.98	20,473.92	30,048.88
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	10,062.56	7,176.76	7,381.83	24,606.98	20,473.92	30,048.88
	Tax expense						
	a) Current Year Tax	2,198.12	1,444.47	1,436.70	5,059.27	4190.25	5,883.75
	b) Short/ (Excess) Provision of earlier year	-	-	-	-	-	(306.27)
	c) Deferred Tax	465.64	270.04	668.80	1,141.31	1118.57	2,781.51
6	Total Tax Expenses	2,663.77	1,714.51	2,105.50	6,200.59	5,308.82	8,358.99
7	Profit for the period (5-6)	7,398.79	5,462.25	5,276.33	18,406.39	15,165.10	21,689.89
	Other Comprehensive Income (OCI)						
	a. Items that will be reclassified to Statement of Profit and Loss	(184.87)	(276.78)	29.48	(389.45)	7.40	(45.13)
	b. Items that will not be reclassified to Statement of Profit and Loss	(85.96)	-	-	(109.82)	-	-
8	Total Other Comprehensive Income	(270.83)	(276.78)	29.48	(499.27)	7.40	(45.13)
9	Total Comprehensive Income for the period (7+8)	7,127.96	5,185.47	5,305.81	17,907.12	15,172.50	21,644.76
	Profit for the period attributable to:						
	-Owners of the Company	7,398.79	5,462.25	5,276.33	18,406.39	15,165.10	21,689.89
	-Non-controlling interest	-	-	-	-	-	-
	Other Comprehensive Income for the period attributable to:						
	-Owners of the Company	7,127.96	5,185.47	5,305.81	17,907.12	15,172.50	21,644.76
	-Non-controlling interest	-	-	-	-	-	-
10	Earnings per Equity share:						
	Basic Earnings Per Share (EPS) (₹)	8.16	6.03	5.82	20.31	16.73	23.93
	Diluted Earnings Per Share (EPS) (₹)	8.16	6.02	5.82	20.30	16.73	23.93
11	Paid-up Equity Share Capital (Face Value of Rs. 5/-each)	4,531.30	4,531.30	4,531.30	4,531.30	4,531.30	4,531.30
12	Reserves excluding Revaluation Reserves as at Balance Sheet date						171,172.62

- The Financial Results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- The above Results for the Quarter and Nine Months ended December 31, 2024, have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on February 5, 2025
- As on December 31, 2024, the Company has 2 (Two) direct subsidiaries, namely, Aarti Pharmachem Limited, Aarti USA Inc, and 1 (One) Jointly Controlled Entity namely Ganesh Polychem Limited.
- The aforesaid financial results will be uploaded on the Company's website at www.aartipharmalabs.com and are also available on the website of BSE limited www.bseindia.com & the National Stock Exchange of India Limited www.nseindia.com
- Figures for the previous period have been regrouped or rearranged wherever necessary.

Place : Mumbai
Date: 5th February 2025



For Aarti Pharamalabs Limited

Hetal Gogri Gala
Vice Chairperson & Managing Director


AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

Independent Auditors' Report on Audit of Standalone Financial Results

To The Board of Directors of
Aarti Pharmalabs Limited

Report on the Audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone financial results of Aarti Pharmalabs Limited ('the Company') for the quarter and period ended 31 December 2024 ('standalone financial results') attached herewith, being submitted by the Company pursuant to regulatory requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial results:

1. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
2. give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS-34") prescribed under section 133 of the Companies Act 2013 read with relevant rules thereunder and other accounting principles generally accepted in India of the net profit and total other comprehensive income, and other financial information of the Company for the quarter and period ended 31st December 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Directors' Responsibilities for the Standalone Financial Results

These quarterly standalone financial results have been prepared on the basis of the interim financial statements. The Company's Management and the Board of Directors are responsible for the preparation of these standalone financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.



This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management and the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit

evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No.: 103264W



Uday Girjapure
Partner
Membership No. 161776
UDIN: 25161776BMOHQZ7611



Date: 5th February 2025
Place: Mumbai

Independent Auditors' Report on Audit of Consolidated Financial Results

To The Board of Directors of
Aarti Pharmed Labs Limited

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying Statement of Consolidated Financial Results of Aarti Pharmed Labs Limited ('Holding Company'), its subsidiaries and joint controlled entity (Holding Company together with its subsidiaries and joint controlled entity referred to as 'the Group') for the quarter and period ended 31st December 2024 ('the Statement'), being submitted by the Holding Company pursuant to regulatory requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements / financial information of subsidiaries (refer to other matter paras), the Statement:

- includes the results of the following entities:
 - Subsidiaries**
 - Aarti USA Inc
 - Aarti Pharmachem Limited
 - Jointly Controlled Entity**
 - Ganesh Polychem Limited
- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS-34") prescribed under section 133 of the Companies Act 2013 read with relevant rules thereunder and other accounting principles generally accepted in India of the consolidated net profit and consolidated total other comprehensive income and other financial information of the Group for quarter and period ended 31 December 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other



Matters” paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated financial results.

Management's and Board of Directors' Responsibilities for the Consolidated Financial Results.

These Consolidated Financial Results have been prepared on the basis of the consolidated financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these Consolidated Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated Financial Results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the Consolidated Financial Results, the respective Management and Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's Internal controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group or any of the group entities to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Results, including the disclosures, and whether the Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

Obtain sufficient appropriate audit evidence regarding the Financial Results/financial information of the entities within the Group to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in the section titled 'Other Matters' in this audit report.

Materiality is the magnitude of misstatements in the Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Results.

We communicate with those charged with governance of the Holding Company and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

I. Financial Results of Subsidiaries not audited by us.

- a) The consolidated financial results include the audited financial results of 1 subsidiary and 1 Jointly controlled entity whose financial Results reflect total revenue from operation of Rs. 3,533 Lakhs and Rs. 11,207 Lakhs (before consolidation adjustments) and total net profit after tax of Rs. 763 Lakhs and Rs. 2,022 Lakhs (before consolidation adjustments) and total net comprehensive income of Rs. 766 Lakhs and Rs. 2,086 Lakhs (before consolidated adjustments) for the quarter and period ended 31st December 2024 respectively as considered in the consolidated financial results, which have been audited by their respective independent auditors. The independent auditors' reports on Financial Results of these entities have been furnished to us and our opinion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.
- b) The consolidated financial results include the audited financial results of 1 foreign subsidiary whose financial Results/ financial information reflect total revenues of Rs. 3,220 Lakhs and Rs. 20,312 Lakhs (before consolidation adjustments) and total net profit after tax of Rs.70 Lakhs and Rs. 410 Lakhs (before consolidation adjustments) and total net comprehensive income of Rs. (16) Lakhs and Rs. 175 Lakhs (before consolidated adjustments) for the quarter and period ended 31st December 2024 respectively as considered in the consolidated financial results. The independent auditors' reports on the Financial Results of this entity have been furnished to us and our opinion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of this entity, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

Our opinion is not modified in respect of the above matter.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No.: 103264W



Uday Girjapure
Partner
Membership No. 161776
UDIN: 25161776BMOHRA2640
Date: 5th February 2025
Place: Mumbai





- B) Statement On Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. – Not Applicable
- C) Format for Disclosing Outstanding Default On Loans and Debt Securities – NIL
- D) Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) – Not Applicable for this quarter
- E) Statement On Impact of Audit Qualifications (For Audit Report with Modified Opinion) Submitted Along with Annual Audited Financial Results (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) – Not Applicable for this quarter

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655